What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).”In the company’s words, NCT05248230 on ClinicalTrials.gov
- Tested for
- Cystic Fibrosis Lung
- Main trialPhase 2
- “This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.”In the company’s words, NCT05248230 on ClinicalTrials.gov
Other drugs for Cystic Fibrosis Lung
- ELX/TEZ/IVAVertex Pharmaceuticals · Phase 3
- IvacaftorVertex Pharmaceuticals · Phase 3
- VNZ/TEZ/D-IVAVertex Pharmaceuticals · Phase 3
- RCT2100ReCode Therapeutics · Phase 2
- SP-101Spirovant Sciences, Inc. · Phase 1/2
- ARCT-032Arcturus Therapeutics, Inc. · Phase 2
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jun 2027 | 4D-710 in Adult Patients With Cystic Fibrosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026